Global Alpha Emitter Market Growth and Share Analysis by Leading Countries, Top Key Players, Regions, Forecast to 2019-2024

Alpha Emitter

The primary goal of this Global Alpha Emitter Market report is to maintain the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the global Alpha Emitter market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the global market. The impact of prevailing regulatory scenario on both regional and worldwide Alpha Emitter market is provided in detail in the report.

Get Sample Copy of Alpha Emitter Market Report @

Key Market Trends:

Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period

The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.

The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.

Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.

Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future.

In addition, a recent Phase I clinical trial involving At-211-MX35 F (ab′) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.

Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.

Alpha Emitter Market Covers Key Players:

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd

    Ask for Discount at

    Geographical Landscape:

    This Report Focuses on the Alpha Emitter in the Global market, especially in North America, China, Europe, Japan, Southeast Asia, India. This report categorizes the market based on manufacturers, regions, type, and application

    Market Overview:

  • The global alpha emitter market was valued at USD 506.5 million in 2018, and it is estimated to be valued at USD 3302.99 million by 2024 while witnessing a CAGR of 36.69% over the forecast period of 2019-2024. Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy, and the growing number of patients with cardiac and cancer ailments.
  • Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Consumers are now increasingly aware of the potential benefits of targeted therapies to cure such ailments.
  • Furthermore, radioimmunotherapy with short-ranged and high-efficiency α-particles is a striking and promising treatment approach. α-particles have an advantage in targeted therapy because of their exceptionally high cell-killing ability.
  • However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways, across the world.
  • Report Highlights:

    – The report provides a detailed analysis on current and future market trends to identify the investment opportunities

    – Market forecasts till 2024, using estimated market values as the base numbers

    – Key market trends across the business segments, Regions and Countries

    – Key developments and strategies observed in the market

    – Market Dynamics such as Drivers, Restraints, Opportunities and other trends

    – In-depth company profiles of key players and upcoming prominent players

    – Growth prospects among the emerging nations through 2024

    – Alpha Emitter Market opportunities and recommendations for new investments

    Price Of Report: $ 4250 (SUL)

    Purchase Alpha Emitter Market Report @

    Detailed TOC of Alpha Emitter Market Research Report 2019 – 2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy
    4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments
    4.3 Market Restraints
    4.3.1 Short Half-life of Radiopharmaceuticals
    4.3.2 Stringent Regulatory Framework and Reimbursement Issues
    4.3.3 Need for High Capital Investment
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 Type of Radionuclide
    5.1.1 Terbium (Tb-149)
    5.1.2 Astatine (At-211)
    5.1.3 Bismuth (Bi-212)
    5.1.4 Actinium (Ac-225)
    5.1.5 Radium (Ra-223)
    5.1.6 Lead (Pb-212)
    5.1.7 Bismuth (Bi -213)
    5.2 Medical Application
    5.2.1 Glioma
    5.2.2 Melanoma
    5.2.3 Pancreatic Cancer
    5.2.4 Ovarian Cancer
    5.2.5 Thyroid
    5.2.6 Bone Metastasis
    5.2.7 Lymphoma
    5.2.8 Endocrine Tumors
    5.2.9 Other Medical Applications
    5.3 Geography
    5.3.1 North America United States Canada Mexico
    5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
    5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
    5.3.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 Actinium Pharmaceutical Inc.
    6.1.2 Alpha Tau Medical Ltd
    6.1.3 Bayer AG
    6.1.4 Fusion Pharmaceuticals
    6.1.5 IBA Radiopharma Solutions
    6.1.6 RadioMedix Inc.
    6.1.7 Telix Pharmaceuticals Ltd


    About Industry Research:

    Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

    Contact Us:

    Name: Ajay More

    Organization: Industry Research

    Phone: +44 20 3239 8187 / +14242530807

    Email: [email protected]

    Our latest Report: Microalgae Market Report 2019 Analysis by Market Players, Size, Share, Growth Rate, Opportunities, Drivers, and Risk Factor Forecast to 2023